February 8, 2023

4D Molecular Therapeutics to Participate in the SVB Securities Global Biopharma Conference

February 8, 2023 Download PDF EMERYVILLE, Calif., Feb. 08, 2023 (GLOBE NEWSWIRE) — 4D Molecular Therapeutics (Nasdaq: FDMT, ‘4DMT’), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, today announced that the Company will present at the SVB Securities Global Biopharma Conference. David Kirn, M.D., Co-founder and Chief Executive Officer of…

View details